Tag: S1PR2
-
The introduction of pharmacodynamic (PD) biomarkers in oncology has implications for
The introduction of pharmacodynamic (PD) biomarkers in oncology has implications for design of clinical protocols from preclinical data as well as for predicting clinical outcomes from early clinical data. of sufferers subjected to subtherapeutic dosages. The energy of preclinical data could possibly be enhanced by fitted the info to a PK model. This managed to…